Histologic Regression Tied to Lower Odds of SLN Positivity

This article originally appeared here.
Share this content:
Histologic Regression Tied to Lower Odds of SLN Positivity
Histologic Regression Tied to Lower Odds of SLN Positivity

FRIDAY, Sept. 4, 2015 (HealthDay News) -- For patients with primary melanoma, the risk of sentinel lymph node (SLN) positivity is significantly lower for those with histologic regression, according to a review published online Sept. 2 in JAMA Dermatology.

Simone Ribero, M.D., Ph.D., from the University of Turin in Italy, and colleagues conducted a systematic review to examine whether regression affects SLN status. The authors reviewed 94 articles; the analysis included 14 studies with 10,098 patients.

The researchers found that the likelihood of SLN positivity was lower for patients with versus those without regression (odds ratio, 0.56). The likelihood of SLN positivity was lower for patients with regression enrolled in high-quality studies (odds ratio, 0.48) compared with results of lower-quality studies (odds ratio, 0.73). There was no evidence of publication bias on examination of the funnel plot.

"The results of this analysis showed that the risk of SLN positivity was significantly lower in patients with histologic regression compared with those without," the authors write. "Regression may be used in these cases to make a selection of which patients should be the most appropriate for this procedure."

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »